Careful Drug History is Key: Dr Abdul Mannan on Diagnosing Drug-Induced Immune Haemolytic Anaemia
Dr Abdul Mannan, Consultant Haematologist at Betsi Cadwaladr University Health Board, posted on LinkedIn:
”Sometimes diagnosing drug-induced immune haemolytic anaemia (DIIHA) feels like chasing a unicorn among zebras. What looks like a straightforward AIHA can suddenly turn on its head when a culprit drug is revealed.
A decade of pharmacovigilance data from France has now reminded us that the “usual suspects” (antibiotics, anti-inflammatories, etc.) are no longer alone – immune checkpoint inhibitors have officially joined the list.
The lesson is clear:
Never underestimate the power of a careful drug history.
A positive DAT is not the end of the story – it’s the start of the detective work.
Always challenge your diagnostic assumptions before risking re-exposure.
As our therapeutic toolbox expands, so too does the responsibility to spot these rare but serious events. Grateful for the international haematology community that keeps pushing vigilance forward and protecting patients.”
Read the full article here.
Title: A decade of pharmacovigilance in France: Immune checkpoints join the list of usual suspects for drug-induced immune haemolytic anaemia
Authors: Guillaume Brenac, Anne Dautriche, Romane Freppel, Anthony Facile, Bruno Revol, Mathilde Beurrier, Bernard Bonnotte, Sylvain Audia
Stay updated with Hemostasis Today.
-
Nov 3, 2025, 08:23The 1st Participant in A New CHECK-NIRS Clinical Study is Enrolled!
-
Nov 3, 2025, 08:15Bert van Meurs Shares the New Late-breaking Results from the iMODERN Trial
-
Nov 3, 2025, 07:10Lisa Shea Shares Key Takeaways from NORD Summit 2025
-
Nov 3, 2025, 06:49Darshan Doshi on Results of iMODERN and ILIAS ANOCA Studies Presented at TCT 2025
-
Nov 2, 2025, 14:172019 ESC/EAS Guidelines for the Management of Dyslipidaemias Discussion with Lale Tokgözoğlu and Jeanine Roeters van Lennep
-
Nov 3, 2025, 09:13Claudio Carrubba on How Timing Truly Matters in Trauma Embolization
-
Nov 3, 2025, 08:46Rachel Lamerton and Colleagues on Activation of Platelets in Flow Cytometry
-
Nov 3, 2025, 04:56Nirupama Ramadas and Erica Sparkenbaugh on Thromboinflammation in SCD
-
Nov 2, 2025, 14:21Claude Franceschi: I Advise You to Understand the Hemodynamic Pathophysiology of Venous Diseases Rather than Blindly Applying Ablation Techniques or Venous Stent Placement
-
Nov 2, 2025, 14:15Krishna Aragam: Why are (DCM) and Heart Failure About Twice as Common in Individuals of Self-Identified Black Race?
-
Oct 29, 2025, 07:31The Use of Artificial Intelligence to Improve Detection of Acute Incidental Pulmonary Emboli - JTH
-
Oct 29, 2025, 07:05Shrinidhi Nathany: AI in Diagnostic Medicine
-
Oct 28, 2025, 07:02Aya Berman: AI Model for Predicting Bacteremia
-
Oct 28, 2025, 06:55The New Era of Genomics, AI and Cell Therapy in Hematology and Infectious Diseases
-
Oct 28, 2025, 06:49Lukas Gaats: Researchers Are Building Reproductive Organoids
-
Nov 3, 2025, 09:24Stephen Cornelissen: It’s Not Just About Emergencies — It’s About Everyday Care, Chronic Conditions and Hope
-
Nov 3, 2025, 06:57Maria Elisa Mancuso Reflects on 2025 Annual Congress of the Italian Association of Hemophilia Centres
-
Nov 3, 2025, 05:46Chandra Viswanathan: When Blood Safety Fails, We All Bleed - A Call for Reform and Responsibility
-
Nov 2, 2025, 14:17Anamaria B: Your Mother Still Runs Part of Your DNA
-
Nov 2, 2025, 10:57Paul Bolaji on Launching The First Centralised Nigerian National Stroke Registry